(CercleFinance.com) – The group presented the results of the Phase 3 study on donanemab at the Alzheimer’s Association conference and published in JAMA.
‘Donanemab significantly slowed cognitive and functional decline in Alzheimer’s disease patients with early, amyloid-positive symptoms, thereby reducing the risk of disease progression. Nearly half of early-stage disease participants treated with donanemab did not experience clinical progression after one year,’ the group says.
Further subpopulation analyzes presented live showed that study participants with the earliest stage of the disease experienced even greater benefits, with a 60% slower decline compared to placebo.
‘The positive results of the TRAILBLAZER-ALZ 2 study bring hope to people with Alzheimer’s disease who urgently need new treatment options. This is the first phase 3 disease-modifying study to replicate the positive clinical results seen in a previous study,” said Anne White, executive vice president of Eli Lilly and Company and president of Lilly Neuroscience.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
